nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2018-22-1-9-28nefr-328Research ArticleПЕРЕДОВАЯ СТАТЬЯLEADING ARTICLEКУРЕНИЕ И ПОЧКИSMOKING AND KIDNEYSРумянцевА. Ш.RumyantsevA. Sh.

Румянцев Александр Шаликович - профессор, доктор медицинских наук, кафедра факультетской терапии.

199106,  Санкт-Петербург,  21-я  линия  В.О.,  д.  8а, +7 (812) 326-03-26

Alexandr Sh.Rumyantsev - Prof.,MD, PhD, DMedSci, Department of Faculty Therapy, Department of Faculty Therapy.

199106, Saint Petersburg, V.O., 21 line 8a, +7(812) 326-03-26

rash.56@mail.ruЛындинаМ. Л.LyndinaM. L.

Мария Леонидовна Лындина - кандидат медицинских наук, кафедра факультетской терапии, ассистент

199106, Санкт-Петербург, 21-я линия В.О., д. 8а, (812) 326-03-26

Maria L. Lyndina - MD, PhD Assistant professor, Department of Faculty Therapy.

199106, St-Petersburg, 21 line V.O., build 8a, (812) 326-03-26

A777KA@gmail.comШишкинА. Н.ShishkinA. N.

Шишкин Александр Николаевич - проф., доктор медицинских наук, кафедра факультетской терапии, заведующий.

199106, Санкт-Петербург, 21-я линия В.О., д. 8а, Тел.: (812) 326-03-26

Alexandr N. Shishkin - MD, PhD, DMedSci, Prof., Department of Faculty Therapy.

199106, St-Petersburg, 21 line V.O., build 8a, (812) 326-03-26

alexshishkin@bk.ruСанкт-Петербургский государственный университет; Первый Санкт-Петербургского государственный медицинский университет им. И.П. ПавловаРоссияSaint Petersburg State UniversityRussian FederationСанкт-Петербургский государственный университетРоссияSaint Petersburg State UniversityRussian Federation201829012018221928Copyright © Румянцев А.Ш., Лындина М.Л., Шишкин А.Н., 20182018Румянцев А.Ш., Лындина М.Л., Шишкин А.Н.Rumyantsev A.S., Lyndina M.L., Shishkin A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/328

Табакокурение является основным модифицируемым фактором риска развития сердечно-сосудистых,  респираторных, онкологических заболеваний, преждевременной инвалидности и смертности. В статье обобщены сведения об острых и хронических влияниях табакокурения на состояние почек у здоровых людей, а также  на развитие и прогрессирование хронической болезни почек. Рассматриваются различные механизмы воздействия не только никотина, но и мелкодисперсных компонентов табачного дыма. Обсуждается развитие никотиновой зависимости при использовании основных видов табачных изделий, таких как сигареты, кальянный табак, электронные сигареты.

Tobacco smoking is the  main  modifiable risk factor for cardiovascular and  respiratory diseases, cancer, premature disability and  mortality. The article summarizes information about acute and  chronic effects of tobacco smoking on the  state of the kidneys in healthy people, as well as on the development and  progression of chronic kidney  disease. Various mechanisms of influence not only of nicotine, but also fine-dispersed components of tobacco smoke are considered. It discusses the development of nicotine dependence when using the main types of tobacco products, such as cigarettes, hookah tobacco, electronic cigarettes.

курениекомпоненты табачного дыманикотинхроническая болезнь почекsmokingtobacco smoke componentsnicotinechronic kidney diseaseReferencesWorld Development Indicators database, World Bank, 15 December 2017World Development Indicators database, World Bank, 15 December 2017Игнатова О. Сигареты выходят из моды. Российская газета – Федеральный выпуск №7411 (245)Игнатова О. Сигареты выходят из моды. Российская газета – Федеральный выпуск №7411 (245)WHO report on the global tobacco epidemic, 2017: monitoring tobacco use and prevention policies. Geneva: World Health Organization; 2017; 135WHO report on the global tobacco epidemic, 2017: monitoring tobacco use and prevention policies. Geneva: World Health Organization; 2017; 135Gandini S., Botteri E., Iodice S. et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer. 2008;122(1):155-164.Gandini S., Botteri E., Iodice S. et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer. 2008;122(1):155-164.National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266Shibuya K., Ciecierski C., Guindon E. et al. WHO Framework Convention on Tobacco Control. BMJ. 2003;327(7407):154-157Shibuya K., Ciecierski C., Guindon E. et al. WHO Framework Convention on Tobacco Control. BMJ. 2003;327(7407):154-157Gaworski C.L., Oldham M.J., Wagner K.A. et al. An evaluation of the toxicity of 95 ingredients added individually to experimental cigarettes: approach and methods. Inhal Toxicol. 2011;23 Suppl 1:1-12. doi: 10.3109/08958378.2010.543187Gaworski C.L., Oldham M.J., Wagner K.A. et al. An evaluation of the toxicity of 95 ingredients added individually to experimental cigarettes: approach and methods. Inhal Toxicol. 2011;23 Suppl 1:1-12. doi: 10.3109/08958378.2010.543187Андреева Т.И., Красовский К.С. Табак и здоровье. – Киев, 2004.: 224 с.Андреева Т.И., Красовский К.С. Табак и здоровье. – Киев, 2004.: 224 с.Neergaard J.M., Singh P., Job J., Montgomery S. Waterpipe smoking and nicotine exposure: a review of the current evidence. Nicotine Tobacco Research. 2007; 9: 987-994Neergaard J.M., Singh P., Job J., Montgomery S. Waterpipe smoking and nicotine exposure: a review of the current evidence. Nicotine Tobacco Research. 2007; 9: 987-994Cobb C.O., Ward K.D., Maziak W., Shihadeh A.L., Eisenberg T. Waterpipe tobacco smoking: an emerging health crisis in the United States. American Journal of Health Behaviour; 2010; 34: 275-285Cobb C.O., Ward K.D., Maziak W., Shihadeh A.L., Eisenberg T. Waterpipe tobacco smoking: an emerging health crisis in the United States. American Journal of Health Behaviour; 2010; 34: 275-285O'Connor R.J. Non-cigarette tobacco products: What have we learned and where are we headed? Tob Control . 2012 March; 21(2): 181–190. doi:10.1136/tobaccocontrol-2011-050281O'Connor R.J. Non-cigarette tobacco products: What have we learned and where are we headed? Tob Control . 2012 March; 21(2): 181–190. doi:10.1136/tobaccocontrol-2011-050281Streppel M.T., Boshuizen H.C., Ock M.C. et al. Mortality and life expectancy in relation to long-term cigarette, cigar and pipe smoking: the Zutphen Study. Tob Control. 2007;16(2):107- 113. DOI: 10.1136/tc.2006.017715Streppel M.T., Boshuizen H.C., Ock M.C. et al. Mortality and life expectancy in relation to long-term cigarette, cigar and pipe smoking: the Zutphen Study. Tob Control. 2007;16(2):107- 113. DOI: 10.1136/tc.2006.017715Rabinoff M., Caskey N., Rissling A. et al. Pharmacological and Chemical Effects of Cigarette Additives. Am J Public Health. 2007; 97(11): 1981–1991. doi: 10.2105/AJPH.2005.078014Rabinoff M., Caskey N., Rissling A. et al. Pharmacological and Chemical Effects of Cigarette Additives. Am J Public Health. 2007; 97(11): 1981–1991. doi: 10.2105/AJPH.2005.078014Huang S.J., Xu Y.M., Lau A.T.Y. Electronic cigarette: A recent update of its toxic effects on humans. J Cell Physiol. 2017 Dec 7. doi: 10.1002/jcp.26352. [Epub ahead of print]Huang S.J., Xu Y.M., Lau A.T.Y. Electronic cigarette: A recent update of its toxic effects on humans. J Cell Physiol. 2017 Dec 7. doi: 10.1002/jcp.26352. [Epub ahead of print]Colombo E.S., Davis J., Makvandi M. et al. Effects of nicotine on cardiovascular remodeling in a mouse model of systemic hypertension. Cardiovascular toxicology 2013; 13(4):364-369Colombo E.S., Davis J., Makvandi M. et al. Effects of nicotine on cardiovascular remodeling in a mouse model of systemic hypertension. Cardiovascular toxicology 2013; 13(4):364-369Golli NE, Jrad-Lamine A, Neffati H et al. Impact of ecigarette refill liquid exposure on rat kidney. Regulatory toxicology and pharmacology. RTP 2016; 77:109-116Golli NE, Jrad-Lamine A, Neffati H et al. Impact of ecigarette refill liquid exposure on rat kidney. Regulatory toxicology and pharmacology. RTP 2016; 77:109-116Rubenstein DA, Hom S, Ghebrehiwet B, Yin W. 2015. Tobacco and e-cigarette products initiate Kupffer cell inflammatory responses. Molecular immunology 67(2 Pt B):652-660Rubenstein DA, Hom S, Ghebrehiwet B, Yin W. 2015. Tobacco and e-cigarette products initiate Kupffer cell inflammatory responses. Molecular immunology 67(2 Pt B):652-660Lauterstein D.E., Tijerina P.B., Corbett K. et al. Frontal Cortex Transcriptome Analysis of Mice Exposed to Electronic Cigarettes During Early Life Stages. International journal of environmental research and public health 2016;13(4):417Lauterstein D.E., Tijerina P.B., Corbett K. et al. Frontal Cortex Transcriptome Analysis of Mice Exposed to Electronic Cigarettes During Early Life Stages. International journal of environmental research and public health 2016;13(4):417Benowitz NL, Henningfield JE. Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N Engl J Med. 1994;331(2):123-125Benowitz NL, Henningfield JE. Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N Engl J Med. 1994;331(2):123-125Sofuoglu M., LeSage M.G. The Reinforcement Threshold for Nicotine as a Target for Tobacco Control. Drug Alcohol Depend. 2012; 125(1-2): 1–7. doi: 10.1016/j.drugalcdep.2012.04.023Sofuoglu M., LeSage M.G. The Reinforcement Threshold for Nicotine as a Target for Tobacco Control. Drug Alcohol Depend. 2012; 125(1-2): 1–7. doi: 10.1016/j.drugalcdep.2012.04.023Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334(1):13-18 DOI: 10.1056/NEJM199601043340103Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334(1):13-18 DOI: 10.1056/NEJM199601043340103Pinto-Sietsma S.J., Mulder J., Janssen W.M. et al. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 2000; 133: 585–591Pinto-Sietsma S.J., Mulder J., Janssen W.M. et al. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 2000; 133: 585–591Halimi J.M., Giraudeau B., Vol S. et al. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int. 2000; 58(3):1285-1292Halimi J.M., Giraudeau B., Vol S. et al. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int. 2000; 58(3):1285-1292Cockcroft D.W., Gault M.H. Prediction of creatinine clearance Panarelli W, De Santo NG: Microalbuminuria in nondiabetic from serum creatinine. Nephron 1976; 16:31–41Cockcroft D.W., Gault M.H. Prediction of creatinine clearance Panarelli W, De Santo NG: Microalbuminuria in nondiabetic from serum creatinine. Nephron 1976; 16:31–41Halimi J-M., Philippon C., Mimran A. Contrasting renal effects of nicotine in smokers and never-smokers. Nephrol Dial Transplant 1998;13:940–944Halimi J-M., Philippon C., Mimran A. Contrasting renal effects of nicotine in smokers and never-smokers. Nephrol Dial Transplant 1998;13:940–944Bleyer AJ, Shemanski LR, Burke GL et al. Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population. Kidney Int 2000; 57: 2072–2079Bleyer AJ, Shemanski LR, Burke GL et al. Tobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population. Kidney Int 2000; 57: 2072–2079Tozawa M, Iseki K, Iseki C, Oshiro S et al. Influence of smoking and obesity on the development of proteinuria. Kidney Int 2002; 62: 956–962Tozawa M, Iseki K, Iseki C, Oshiro S et al. Influence of smoking and obesity on the development of proteinuria. Kidney Int 2002; 62: 956–962Haroun MK, Jaar BG, Hoffman SC et al. ,Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003; 14: 2934–2941Haroun MK, Jaar BG, Hoffman SC et al. ,Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003; 14: 2934–2941Stengel B, Tarver-Carr ME, Powe NR et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 2003; 14: 479–487Stengel B, Tarver-Carr ME, Powe NR et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 2003; 14: 479–487Fox CS, Larson MG, Leip EP et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844–850Fox CS, Larson MG, Leip EP et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844–850Baggio B, Budakovic A, Perissinotto E et al. Atherosclerotic risk factors and renal function in the elderly: the role of hyperfibrinogenaemia and smoking. Results from the Italian Longitudinal Study on Ageing (ILSA).Nephrol Dial Transplant 2005; 20: 114–123Baggio B, Budakovic A, Perissinotto E et al. Atherosclerotic risk factors and renal function in the elderly: the role of hyperfibrinogenaemia and smoking. Results from the Italian Longitudinal Study on Ageing (ILSA).Nephrol Dial Transplant 2005; 20: 114–123Shankar A, Klein R, Klein BE. The association among smoking, heavy drinking, and chronic kidney disease. Am J Epidemiol 2006; 164: 263–271Shankar A, Klein R, Klein BE. The association among smoking, heavy drinking, and chronic kidney disease. Am J Epidemiol 2006; 164: 263–271Ishani A, Grandits GA, Grimm RH et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol 2006; 17: 1444–1452Ishani A, Grandits GA, Grimm RH et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol 2006; 17: 1444–1452Yamagata K, Ishida K, Sairenchi T et al. Risk factors for chronic kidney disease in a community-based population: a 10year follow-up study. Kidney Int 2007; 71: 159–166Yamagata K, Ishida K, Sairenchi T et al. Risk factors for chronic kidney disease in a community-based population: a 10year follow-up study. Kidney Int 2007; 71: 159–166Yamamoto R, Nagasawa Y, Shoji T et al. Cigarette smoking and progression of IgA nephropathy. Am J Kidney Dis 2010; 56: 313–324Yamamoto R, Nagasawa Y, Shoji T et al. Cigarette smoking and progression of IgA nephropathy. Am J Kidney Dis 2010; 56: 313–324Nogueira JM, Haririan A, Jacobs SC et al. Cigarette smoking, kidney function, and mortality after live donor kidney transplant. Am J Kidney Dis 2010; 55: 907–915Nogueira JM, Haririan A, Jacobs SC et al. Cigarette smoking, kidney function, and mortality after live donor kidney transplant. Am J Kidney Dis 2010; 55: 907–915Scott L.J., Warram J.H., Hanna L.S. et al. A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes. Diabetes 2001; 50: 2842–2849Scott L.J., Warram J.H., Hanna L.S. et al. A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes. Diabetes 2001; 50: 2842–2849de Boer I.H., Sibley S.D., Kestenbaum B. Et al. Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol 2007; 18: 235–243de Boer I.H., Sibley S.D., Kestenbaum B. Et al. Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol 2007; 18: 235–243Perry Jr. H.M., Miller J.P., Fornoff J.R et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995; 25 (4 Pt 1): 587–594Perry Jr. H.M., Miller J.P., Fornoff J.R et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995; 25 (4 Pt 1): 587–594Sud M., Tangri N., Levin A. et al. CKD stage at nephrology referral and factors influencing the risks of ESRD and death. Am J Kidney Dis. 2014;63(6):928-36. doi: 10.1053/j.ajkd.2013.12.008Sud M., Tangri N., Levin A. et al. CKD stage at nephrology referral and factors influencing the risks of ESRD and death. Am J Kidney Dis. 2014;63(6):928-36. doi: 10.1053/j.ajkd.2013.12.008Obi Y, Kimura T, Nagasawa Y et al. Impact of age and overt proteinuria on outcomes of stage 3 to 5 chronic kidney disease in a referred cohort. Clin J Am Soc Nephrol 2010; 5:1558–1565Obi Y, Kimura T, Nagasawa Y et al. Impact of age and overt proteinuria on outcomes of stage 3 to 5 chronic kidney disease in a referred cohort. Clin J Am Soc Nephrol 2010; 5:1558–1565Orth S.R., Stockmann A., Conradt C. et al. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 1998; 54: 926–931Orth S.R., Stockmann A., Conradt C. et al. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 1998; 54: 926–931Khalil M.A.M., Tan J., Khamis S. et al. Cigarette Smoking and Its Hazards in Kidney Transplantation Adv Med 2017;2017:6213814. doi: 10.1155/2017/6213814;Khalil M.A.M., Tan J., Khamis S. et al. Cigarette Smoking and Its Hazards in Kidney Transplantation Adv Med 2017;2017:6213814. doi: 10.1155/2017/6213814;Sözen F., Aydemir S., Erdal R., Haberal M. Smoking Behaviors of Renal Transplant Recipients: An Analysis of 113 Patients. Exp Clin Transplant 2016;14(Suppl 3):95-99;Sözen F., Aydemir S., Erdal R., Haberal M. Smoking Behaviors of Renal Transplant Recipients: An Analysis of 113 Patients. Exp Clin Transplant 2016;14(Suppl 3):95-99;Underwood P.W., Sheetz K.H., Cron D.C. et al. Cigarette smoking in living kidney donors: donor and recipient outcomes. Clin Transplant. 2014;28(4):419-422. doi: 10.1111/ctr.12330Underwood P.W., Sheetz K.H., Cron D.C. et al. Cigarette smoking in living kidney donors: donor and recipient outcomes. Clin Transplant. 2014;28(4):419-422. doi: 10.1111/ctr.12330Practice advisory for preanesthesia evaluation: an updated report by the American Society of Anesthesiologists Task Force on Preanesthesia Evaluation. Committee on Standards and Practice Parameters. Anesthesiology. 2012;116(3):522-538. doi: 10.1097/ALN.0b013e31823c1067Practice advisory for preanesthesia evaluation: an updated report by the American Society of Anesthesiologists Task Force on Preanesthesia Evaluation. Committee on Standards and Practice Parameters. Anesthesiology. 2012;116(3):522-538. doi: 10.1097/ALN.0b013e31823c1067Delmonico F; Council of the Transplantation Society. A Report of the Amsterdam Forum On the Care of the Live Kidney Donor: Data and Medical Guidelines. Transplantation. 2005; 79 (6 Suppl): S53-66Delmonico F; Council of the Transplantation Society. A Report of the Amsterdam Forum On the Care of the Live Kidney Donor: Data and Medical Guidelines. Transplantation. 2005; 79 (6 Suppl): S53-66Keles M., Avsar U., Avsar Z. et al. Effect of kidney transplantation on smoking habits of kidney donors. Transplantation Proceedings 2015; 47 (5): 1302-1305Keles M., Avsar U., Avsar Z. et al. Effect of kidney transplantation on smoking habits of kidney donors. Transplantation Proceedings 2015; 47 (5): 1302-1305Kasiske B.L., Chakkera H.A., Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J. of the American Society of Nephrology 2000; 11 (9): 1735-1743Kasiske B.L., Chakkera H.A., Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J. of the American Society of Nephrology 2000; 11 (9): 1735-1743Global Adult Tobacco Survey Collaborative Group. Tobacco Questions for Surveys: A Subset of Key Questions from the Global Adult Tobacco Survey (GATS), 2nd Edition. Atlanta, GA: Centers for Disease Control and Prevention, 2011: 42Global Adult Tobacco Survey Collaborative Group. Tobacco Questions for Surveys: A Subset of Key Questions from the Global Adult Tobacco Survey (GATS), 2nd Edition. Atlanta, GA: Centers for Disease Control and Prevention, 2011: 42Howard R. Microrisks for medical decision analysis. Int J Technol Assess Health Care 1989; 5: 357–370Howard R. Microrisks for medical decision analysis. Int J Technol Assess Health Care 1989; 5: 357–370Spiegelhalter D. How old are you, really? Communicating chronic risk through 'effective age' of your body and organs. BMC Med Inform Decis Mak. 2016 Aug 5;16:104. doi: 10.1186/s12911-016-0342-zSpiegelhalter D. How old are you, really? Communicating chronic risk through 'effective age' of your body and organs. BMC Med Inform Decis Mak. 2016 Aug 5;16:104. doi: 10.1186/s12911-016-0342-zPan A., Wang Y., Talaei M. et al. Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(12):958-67. doi: 10.1016/S2213-8587(15)00316-2Pan A., Wang Y., Talaei M. et al. Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(12):958-67. doi: 10.1016/S2213-8587(15)00316-2Aucella F., Cignarelli M., Lamacchia O., Gesualdo L. Environment, Smoking, Obesity, and the Kidney In: Claudio Ronco Rinaldo Bellomo John Kellum, eds. Critical Care Nephrology, 2nd ed. Saunders, 2009: 1320-1324Aucella F., Cignarelli M., Lamacchia O., Gesualdo L. Environment, Smoking, Obesity, and the Kidney In: Claudio Ronco Rinaldo Bellomo John Kellum, eds. Critical Care Nephrology, 2nd ed. Saunders, 2009: 1320-1324Benowitz N.L., Hukkanen J., Jacob P. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacology. 2009; 192: 29-60Benowitz N.L., Hukkanen J., Jacob P. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacology. 2009; 192: 29-60Moran V.E. Cotinine: Beyond that Expected, More than a Biomarker of Tobacco Consumption. Front Pharmcol. 2012; 3: 173Moran V.E. Cotinine: Beyond that Expected, More than a Biomarker of Tobacco Consumption. Front Pharmcol. 2012; 3: 173Hukkanen J, Jacob P 3rd, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57(1):79-115Hukkanen J, Jacob P 3rd, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57(1):79-115Loukola A., Hallfors J., Korhonen T., Kaprio J. Genetics and smoking. Curr Addict Rep. 2014; 1: 75-82Loukola A., Hallfors J., Korhonen T., Kaprio J. Genetics and smoking. Curr Addict Rep. 2014; 1: 75-82Mishra A., Chaturvedi P., Datta S. et al. Harmful effects of nicotine. Indian J Med Paediatr Oncol. 2015 Jan-Mar;36(1):24-31. doi: 10.4103/0971-5851.151771Mishra A., Chaturvedi P., Datta S. et al. Harmful effects of nicotine. Indian J Med Paediatr Oncol. 2015 Jan-Mar;36(1):24-31. doi: 10.4103/0971-5851.151771Liu C.C., Yeh H.I. Nicotine: A Double-Edged Sword in Atherosclerotic Disease. Acta Cardiol Sin. 2014;30(2):108-113Liu C.C., Yeh H.I. Nicotine: A Double-Edged Sword in Atherosclerotic Disease. Acta Cardiol Sin. 2014;30(2):108-113Jaimes E.A., Tian R.X., Joshi M.S., Raij L. Nicotine augments glomerular injury in a rat model of acute nephritis. Am J Nephrol. 2009;29(4):319-26. doi: 10.1159/000163593Jaimes E.A., Tian R.X., Joshi M.S., Raij L. Nicotine augments glomerular injury in a rat model of acute nephritis. Am J Nephrol. 2009;29(4):319-26. doi: 10.1159/000163593Arany I., Grifoni S., Clark J. S., Csongradi E., Maric C., Juncos L. A. (2011) Chronic nicotine exposure exacerbates acute renal ischemic injury. Am. J. Physiol. Renal Physiol. 301, F125– F133 doi: 10.1152/ajprenal.00041.2011Arany I., Grifoni S., Clark J. S., Csongradi E., Maric C., Juncos L. A. (2011) Chronic nicotine exposure exacerbates acute renal ischemic injury. Am. J. Physiol. Renal Physiol. 301, F125– F133 doi: 10.1152/ajprenal.00041.2011Ateyya H., Nader M.A., Attia G.M., El-Sherbeeny N.A. Influence of alpha-lipoic acid on nicotine-induced lung and liver damage in experimental rats. Can J Physiol Pharmacol. 2017;95(5):492-500. doi: 10.1139/cjpp-2016-0366Ateyya H., Nader M.A., Attia G.M., El-Sherbeeny N.A. Influence of alpha-lipoic acid on nicotine-induced lung and liver damage in experimental rats. Can J Physiol Pharmacol. 2017;95(5):492-500. doi: 10.1139/cjpp-2016-0366Biondo-Simões Mde L., Spelling N.W., Ioshii S. et al. The influence of nicotine on the population of fibroblasts in cutaneous scars in rats. Acta Cir Bras. 2009;24(6):466-470Biondo-Simões Mde L., Spelling N.W., Ioshii S. et al. The influence of nicotine on the population of fibroblasts in cutaneous scars in rats. Acta Cir Bras. 2009;24(6):466-470Holbourn K.P., Acharya K.R., Perbal B. The CCN family of proteins: structure-function relationships. Trends Biochem Sci. 2008;33(10):461-473. doi: 10.1016/j.tibs.2008.07.006Holbourn K.P., Acharya K.R., Perbal B. The CCN family of proteins: structure-function relationships. Trends Biochem Sci. 2008;33(10):461-473. doi: 10.1016/j.tibs.2008.07.006Takeuchi H., Kubota S., Murakashi E. et al. Nicotineinduced CCN2: from smoking to periodontal fibrosis. J. Dent. Res 2010; 89, 34-39Takeuchi H., Kubota S., Murakashi E. et al. Nicotineinduced CCN2: from smoking to periodontal fibrosis. J. Dent. Res 2010; 89, 34-39Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2007;27(1):27-36Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2007;27(1):27-36Coburn R.F. The measurement of endogenous carbon monoxide production. J Appl Physiol 2012; 112: 1949–1955Coburn R.F. The measurement of endogenous carbon monoxide production. J Appl Physiol 2012; 112: 1949–1955Stamellou E., Storz D., Botov S. et al. Different design of enzyme-triggered CO-releasing molecules (ET-CORMs) reveals quantitative differences in biological activities in terms of toxicity and inflammation. Redox Biol. 2014;2:739-748. doi: 10.1016/j.redox.2014.06.002Stamellou E., Storz D., Botov S. et al. Different design of enzyme-triggered CO-releasing molecules (ET-CORMs) reveals quantitative differences in biological activities in terms of toxicity and inflammation. Redox Biol. 2014;2:739-748. doi: 10.1016/j.redox.2014.06.002Kourti M., Jiang W.G., Cai J. Aspects of Carbon Monoxide in Form of CO-Releasing Molecules Used in Cancer Treatment: More Light on the Way. Oxid Med Cell Longev. 2017;2017:9326454. doi: 10.1155/2017/9326454Kourti M., Jiang W.G., Cai J. Aspects of Carbon Monoxide in Form of CO-Releasing Molecules Used in Cancer Treatment: More Light on the Way. Oxid Med Cell Longev. 2017;2017:9326454. doi: 10.1155/2017/9326454Qiao L., Zhang N., Huang J.L., Yang X.Q. Carbon monoxide as a promising molecule to promote nerve regeneration after traumatic brain injury. Med Gas Res. 2017;7(1):45-47. doi: 10.4103/2045-9912.202909Qiao L., Zhang N., Huang J.L., Yang X.Q. Carbon monoxide as a promising molecule to promote nerve regeneration after traumatic brain injury. Med Gas Res. 2017;7(1):45-47. doi: 10.4103/2045-9912.202909Левченкова О.С., Новиков В.Е. Индукторы регуляторного фактора адаптации к гипоксии. Российский медико-биологический вестник им. академика И.П. Павлова 2014; (2): 133-143Левченкова О.С., Новиков В.Е. Индукторы регуляторного фактора адаптации к гипоксии. Российский медико-биологический вестник им. академика И.П. Павлова 2014; (2): 133-143Tanaka T., Nangaku M. The role of hypoxia, increased oxygen consumption, and hypoxia-inducible factor-1 alpha in progression of chronic kidney disease. Curr Opin Nephrol Hypertens. 2010;19(1):43-50. doi: 10.1097/MNH.0b013e3283328eedTanaka T., Nangaku M. The role of hypoxia, increased oxygen consumption, and hypoxia-inducible factor-1 alpha in progression of chronic kidney disease. Curr Opin Nephrol Hypertens. 2010;19(1):43-50. doi: 10.1097/MNH.0b013e3283328eedБобкова И.Н., Козловская Л.В., Рамеева А.С. и др. Клиническое значение определения в моче маркеров эндотелиальной дисфункции и факторов ангиогенеза в оценке тубулоинтерстициального фиброза при хроническом гломерулонефрите. Терапевтический архив 2007; 79 (6): 10-16Бобкова И.Н., Козловская Л.В., Рамеева А.С. и др. Клиническое значение определения в моче маркеров эндотелиальной дисфункции и факторов ангиогенеза в оценке тубулоинтерстициального фиброза при хроническом гломерулонефрите. Терапевтический архив 2007; 79 (6): 10-16Orr S.E., Bridges C.C. Chronic Kidney Disease and Exposure to Nephrotoxic Metals. Int J Mol Sci. 2017;18(5). pii: E1039. doi: 10.3390/ijms18051039Orr S.E., Bridges C.C. Chronic Kidney Disease and Exposure to Nephrotoxic Metals. Int J Mol Sci. 2017;18(5). pii: E1039. doi: 10.3390/ijms18051039Li W.J., Yang C.L., Chow K.C., Kuo T.W. Hexavalent chromium induces expression of mesenchymal and stem cell markers in renal epithelial cells. Mol Carcinog. 2016;55(2):182-192. doi: 10.1002/mc.22268Li W.J., Yang C.L., Chow K.C., Kuo T.W. Hexavalent chromium induces expression of mesenchymal and stem cell markers in renal epithelial cells. Mol Carcinog. 2016;55(2):182-192. doi: 10.1002/mc.22268Jan A.T., Azam M., Siddiqui K. et al. Heavy Metals and Human Health: Mechanistic Insight into Toxicity and Counter Defense System of Antioxidants. Int J Mol Sci. 2015;16(12):29592-630. doi: 10.3390/ijms161226183Jan A.T., Azam M., Siddiqui K. et al. Heavy Metals and Human Health: Mechanistic Insight into Toxicity and Counter Defense System of Antioxidants. Int J Mol Sci. 2015;16(12):29592-630. doi: 10.3390/ijms161226183Carocci A., Catalano A., Lauria G. Lead Toxicity, Antioxidant Defense and Environment. Rev Environ Contam Toxicol. 2016;238:45-67. doi: 10.1007/398_2015_5003Carocci A., Catalano A., Lauria G. Lead Toxicity, Antioxidant Defense and Environment. Rev Environ Contam Toxicol. 2016;238:45-67. doi: 10.1007/398_2015_5003Modaresi A., Nafar M., Sahraei Z. Oxidative stress in chronic kidney disease. Iran J Kidney Dis. 2015;9(3):165-179Modaresi A., Nafar M., Sahraei Z. Oxidative stress in chronic kidney disease. Iran J Kidney Dis. 2015;9(3):165-179George B, You D, Joy MS, Aleksunes LM. Adv Drug Deliv Rev. 2017;116:73-91. doi: 10.1016/j.addr.2017.01.005George B, You D, Joy MS, Aleksunes LM. Adv Drug Deliv Rev. 2017;116:73-91. doi: 10.1016/j.addr.2017.01.005Alevriadou B.R., Shanmughapriya S., Patel A. et al. J R Soc Interface. 2017;14(137). pii: 20170672. doi: 10.1098/rsif.2017.0672Alevriadou B.R., Shanmughapriya S., Patel A. et al. J R Soc Interface. 2017;14(137). pii: 20170672. doi: 10.1098/rsif.2017.0672Островская С.С. Токсические эффекты кадмия. Вестник проблем биологии и медицины. 2014; 3(2): 33-37Островская С.С. Токсические эффекты кадмия. Вестник проблем биологии и медицины. 2014; 3(2): 33-37Magee P.N., Farber E. Toxic liver injury and carcinogenesis. Methylation of rat-liver nucleic acids by dimethylnitrosamine in vivo. Biochem J. 1962; 83:114-124Magee P.N., Farber E. Toxic liver injury and carcinogenesis. Methylation of rat-liver nucleic acids by dimethylnitrosamine in vivo. Biochem J. 1962; 83:114-124Lin X., Wood C.G., Shao L. et al. Risk assessment of renal cell carcinoma using alkaline comet assay. Cancer. 2007;110:282–288Lin X., Wood C.G., Shao L. et al. Risk assessment of renal cell carcinoma using alkaline comet assay. Cancer. 2007;110:282–288Orth S.R., Hallan S.I. Smoking: A Risk Factor for Progression of Chronic Kidney Disease and for Cardiovascular Morbidity and Mortality in Renal Patients—Absence of Evidence or Evidence of Absence? Clin J Am Soc Nephrol 3: 226–236, 2008. doi: 10.2215/CJN.03740907Orth S.R., Hallan S.I. Smoking: A Risk Factor for Progression of Chronic Kidney Disease and for Cardiovascular Morbidity and Mortality in Renal Patients—Absence of Evidence or Evidence of Absence? Clin J Am Soc Nephrol 3: 226–236, 2008. doi: 10.2215/CJN.03740907

The authors declare that there are no conflicts of interest present.